p53-independent Induction of WAF1/CIP1 in Human Leukemia Cells Is Correlated with Growth Arrest Accompanying Monocyte/Macrophage Differentiation

Cancer Research

Volumn 55, Issue 3, 1995, Pages 668-674

  Zhang, Wei ^a,b   Grasso, Luigi ^a,c   McClain, Craig D ^b   Gambel, Anne M ^b   Cha, Ying ^b   Travali, Salvatore ^a,c   Deisseroth, Albert B ^b   Mercer, W Edward ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; CYCLIN DEPENDENT KINASE; DIMETHYL SULFOXIDE; GAMMA INTERFERON; OKADAIC ACID; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P21; PROTEIN P53; RETINOIC ACID;

ARTICLE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN HL 60; CELL STRAIN K 562; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BLOTTING, NORTHERN; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE; CYCLINS; DNA, NEOPLASM; ELECTROPORATION; FLOW CYTOMETRY; GENE EXPRESSION; GENES, P53; GRANULOCYTES; HUMAN; LEUKEMIA, MYELOID, CHRONIC; MONOCYTES; PROTEIN KINASES; PROTEIN P53; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TETRADECANOYLPHORBOL ACETATE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0028985518     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523–526, 1992.
2. Harris, C. C., and Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329: 1318–1327, 1993.
3. Slingerland, J. M., Minden, M. D., and Benchimol, S. Mutation of the p53 gene in human acute myelogenous leukemia. Blood, 77: 1500–1507, 1991.
4. Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M., and Dalla-Favera, R. p53 mutations in human lymphoid malignancies: assiciation with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 88: 5413–5417, 1991.
5. Ahuja, H., Bar-Eli, M., Advani, S. H., Benchimol, S., and Cline, M. J. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc. Natl. Acad. Sci. USA, 86: 6783–6787, 1989.
6. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature (Lond.), 356: 215–221, 1992.
7. Mercer, W. E., Shields, M. T., Amin, M., Suave, G. J., Appella, E., and Ullrich, S. J. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild type p53. Proc. Natl. Acad. Sci. USA, 87: 6166–6170, 1990.
8. Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Bakers, S. J., Vogelstein, B., and Friend, S. H. p53 functions as cell cycle control protein in osteosarcomas. Mol. Cell. Biol., 10: 5772–5781, 1990.
9. Martinez, J., Georgoff, I., Martinez, J., and Levin, A. J. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev., 5: 151–159, 1991.
10. Chen, Y. M., Chen, P. L., Arniaz, N., Goodrich, D., and Lee, W. H. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate. Oncogene, 6: 1779–1780, 1991.
11. Lin, D., Shields, M. T., Ullrich, S. J., Appella, E., and Mercer, W. E. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late Gl-phase. Proc. Natl. Acad. Sci. USA, 89: 9210–9214, 1992.
12. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491–7500, 1992.
13. Donehower, L. A., and Bradley, A. The tumor suppressor p53. Biochim. Biophys. Acta, 1155: 181–205, 1993.
14. Mercer, W. E. Cell cycle regulation and the p53 tumor suppressor protein. Crit. Rev. Eukaryotic Gene Expression, 2: 251–263, 1992.
15. Barak, Y., Juven, T., Haffner, R., and Oren, M. mdm2 expression is induced by wild-type p53 activity. EMBO J., 12: 461–468, 1993.
16. Zambetti, G. P., Bargonetti, J., Walker, K., Prives, C., and Levine, A. J. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev., 6: 1143–1152, 1992.
17. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J. Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataria-Telangiectasia. Cell, 71: 587–597, 1992.
18. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817–825, 1993.
19. 1 cyclin-dependent kinases. Cell, 75: 805–816, 1993.
20. Dulic, V., Kaufmann, W. K., Wilson, S. J., Tishy, T. D., Lees, E., Harper, J. W., Elledge, S. J., and Reed, S. I. p53-dependent inhibition of cyclin-dependent kinases activates in human fibroblasts during radiation-induced G1 arrest. Cell, 76: 1013–1023, 1994.
21. 1 arrest and apoptosis. Cancer Res., 54: 1169–1174, 1994.
22. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.) 369: 574–577, 1994.
23. Michiele, P., Chedid, M., Lin, D., Mercer, W. E., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391–3395, 1994.
24. Kastan, M. B., Radin, A. I., Kuergitz, S. J., Onyekwere, O., Wolkow, C. A., Civin,C. I., Stone, K. D., Woo, T., Ravindravath, Y., and Craig, R. W. Levels of p53 protein increase with maturation in human hematopoietic cells. Cell Res., 51: 4279–4286, 1991.
25. Rivas, C. I., Wisniewski, D., Strife, A., Perez, A., Lambek, C., Bruno, S., Darznkiewicz, Z., and Clarkson, B. Constitutive expression of p53 protein in enriched normal human marrow blast cell populations. Blood, 79: 1982–1986, 1992.
26. Bi, A., Lanza, F., and Goldman, J. M. The involvement of “tumor suppressor” p. 53 in normal and chronic myelogenous leukemia hematopoiesis. Cancer Res., 54: 582–586, 1994.
27. Yonish-Rouach, E., Resnitzky, D., Loeon, J., Sacks, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (Lond.), 532: 345–347, 1991.
28. Ryan, J. J., Danish, R., Gottlieb, C. A., and Clarke, M. F. Cell cycle analysis of p53 induced cell death in murine erythroleukemia cell. Mol. Cell. Biol., 13: 711–717, 1993.
29. Shaulsky, G., Goldfinger, N., Peled, A., and Rotler, B. Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc. Natl. Acad. Sci. USA, 88: 8982–8986, 1991.
30. Soddu, S., Blandino, G., Citro, G., Sardigli, R., Piaggio, G., Ferber, A., Calabretta, B., and Sacchi, A. Wild type p53 gene expression induces granulocyte differentiation of HL60 cells. Blood, 83: 2230–2237, 1994.
31. Zhang, W., Randhawa, G. S., Guo, X-Y., and Deisseroth, A. B. The DNA-binding and transcription-activation abilities of p53 are necessary but not sufficient for its anti-proliferative function. Cell Growth & Differ., 5: 705–710, 1994.
32. Hoy, C. A., Seamer, L. C., and Schimke, R. T. Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the stape of BrdUrd/DNA histogram. Cytometry, 10: 718–725, 1989.
33. Perussia, B., Trinchieri, G., Lebman, D., Jankiewicz, J., Lange, B., and Rovera, G. Monoclonal antibodies that detect differentiation surface antigens in human my-elomonocyte cells. Blood, 59: 382–392, 1982.
34. Rovera, G., O'Brien, T. G., and Diamond L. Induction of differentiation in human promyelocytic leukemia cells by tumor promoters. Science (Washington DC), 204: 868–870, 1979.
35. Plumb, M., Stein, J., and Stein G. Coordinate regulation of multiple histone mRNAs during the cell cycle in Hela cells. Nucleic Acids Res., 11: 2301–2410, 1983.
36. Hirschhorn, R. R., Marashi, F., Baserga, R., Stein, J., and Stein, G. Expression of histone genes in G1 specific temperature sensitive mutant of the cell cycle. Biochemistry, 23: 3731–3736, 1984.
37. Hunter, T. Braking the cycle. Cell, 75: 839–841, 1993.
38. Ewen, M. E., Sluss, H. K., Sherr, E. J., Matsushime, H., Kato, J-Y., and Livingston, D. M. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. CeU, 73: 487–497, 1993.
39. Nevins, J. R. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science (Washington DC), 258: 424–429, 1992.
40. Krek, W., Livingston, D. M., and Shirodkar, S. Binding to DNA and the retinoblastoma gene product promoted by complex formation of different E2F family members. Science (Washington DC), 262: 1557–1560, 1993.
41. Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., and Kato, J-Y. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol., 14: 2066–2076, 1994.
42. Dowdy, S. F., Hinds, P. W., Louie, K., Reed, S. I., Arnold, A., and Weinberg, R. A. Physical interaction of the retinoblastoma protein with human D cyclins. Cell, 73: 499–511, 1993.
43. Hatzfeld, J., Li, M-L., Brown, E. L., Sookdo, H., Levesque, J. P., O'Toole, T., Gurney, C., Clark, S. C., and Hatzfeld, A. Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor B, or RB nucleotides. J. Exp. Med., 174: 925–929, 1991.
44. Lee, E.Y.-H.P., Chang, C-Y., Hu, N., Wang, J.Y.-C., Lai, C-C., Herrup, K., Lee, W-H., and Bradley, A. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature (Lond.), 359: 288–294, 1992.
45. Szabo, E., Pries, L. H., and Birrer, M. J. Constitutive c-Jun expression induces partial macrophage differentiation in U-397 cells. Cell Growth & Differ., 5:439–446, 1994.
46. Kharbanda, S., Datta, R., Rubin, E., Nakamura, T., Hass, R., and Kute, D. Regulation of c-jun expression during induction of monocyte differentiation by okadiac acid. Cell Growth & Differ., 3: 391–399, 1992.
47. Zheng, B., Woo, C. F., and Kuo, J. F. Mitotic arrests and enhanced nuclear protein phosphorylation in human leukemia K562 cells by okadiaic acid, a potent protein phosphatase inhibitor and tumor promoter. J. Biol. Chem., 266:10031–10034, 1991.
48. Kikkawa, Y., Kishimoto, A., and Nishizuka, Y. The protein kinase C family: heterogeneity and its implications. Annu. Rev. Biochem., 58: 31–44, 1989.
49. Haystead, T. A. J., Sim, A. T. R., Carling, D., Honnor, R. C., Tsukitano, Y., Cohen, P., and Hardie, D. G. Effects of the tumor promoter okadaic acid on intracellular protein phosphorylation and metabolism. Nature (Lond.), 337: 78–81, 1989.
50. Cohen, P., Holmes, C. F. B., and Tsukitani, Y. Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem. Sci., 16: 98–102, 1990.
51. McClean, S., and Hill, B. T. An overview of membrane, cytosolic and nuclear proteins associated with expression of resistance to multiple drugs in vitro. Biochim. Biophys. Acta, 1114: 107–127, 1992.